Growth Metrics

Pfizer (PFE) Finished Goods (2016 - 2019)

Pfizer has reported Finished Goods over the past 11 years, most recently at $2.3 billion for Q1 2019.

  • Quarterly Finished Goods fell 19.42% to $2.3 billion in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Mar 2019, down 19.42% year-over-year, with the annual reading at $2.3 billion for FY2018, 21.54% down from the prior year.
  • Finished Goods was $2.3 billion for Q1 2019 at Pfizer, up from $2.3 billion in the prior quarter.
  • Over five years, Finished Goods peaked at $2.9 billion in Q4 2017 and troughed at $1.8 billion in Q2 2015.
  • The 5-year median for Finished Goods is $2.6 billion (2016), against an average of $2.5 billion.
  • Year-over-year, Finished Goods decreased 24.86% in 2015 and then surged 49.89% in 2016.
  • A 5-year view of Finished Goods shows it stood at $2.7 billion in 2015, then dropped by 15.51% to $2.3 billion in 2016, then increased by 25.73% to $2.9 billion in 2017, then fell by 21.54% to $2.3 billion in 2018, then grew by 1.11% to $2.3 billion in 2019.
  • Per Business Quant, the three most recent readings for PFE's Finished Goods are $2.3 billion (Q1 2019), $2.3 billion (Q4 2018), and $2.6 billion (Q3 2018).